share_log

Allogene Therapeutics Q4 2023 GAAP EPS $(0.51) Misses $(0.46) Estimate, Sales $21.000K Miss $23.571K Estimate

Benzinga ·  Mar 14 16:17

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.46) by 10.87 percent. This is a 23.88 percent increase over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $21.000 thousand which missed the analyst consensus estimate of $23.571 thousand by 10.91 percent. This is a 19.23 percent decrease over sales of $26.000 thousand the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment